drug_type
RELEVANT_DRUG
intervention_type
Autologous genetically modified T-cell therapy (CAR T)
drug_description
Autologous, lentiviral-transduced T cells expressing an anti-CD19 chimeric antigen receptor (CAR) with CD3ζ and co-stimulatory domains; designed to recognize CD19 on B-lineage cells and mediate targeted cytotoxicity in B-cell malignancies.
nci_thesaurus_concept_id
C172103
nci_thesaurus_definition
A preparation of CD4+ and CD8+ autologous T-lymphocytes transduced with the lentiviral vector pLTG1563 expressing a chimeric antigen receptor (CAR) specific for the tumor-associated antigen (TAA) CD19, with potential immunostimulating and antineoplastic activities. Upon intravenous administration, the autologous CD19 CAR-expressing CD4+/CD8+ T-cells MB-CART19.1 are directed to and induce selective toxicity in CD19-expressing tumor cells. CD19 antigen is a B-cell specific cell surface antigen expressed in all B-cell lineage malignancies.
drug_mesh_term
Chimeric Antigen Receptor T-Cell Therapy
drug_category
CAR T
drug_class
Cellular Therapy
drug_delivery_route
Intravenous
drug_mechanism_of_action
Autologous lentiviral-transduced T cells engineered to express an anti-CD19 chimeric antigen receptor (CD3ζ plus co-stimulatory domains). Upon binding CD19 on B-lineage cells, the CAR activates T-cell effector functions—proliferation, cytokine release, and cytotoxicity—leading to selective elimination of CD19-positive malignant B cells and B-cell depletion.
drug_name
MB-CART19.1
nct_id_drug_ref
NCT06508775